Barriers to using clozapine in treatment-resistant schizophrenia: systematic review
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Aims and method: To systematically review the literature on barriers to the use of clozapine and identify any interventions for optimizing clozapine use in treatment-resistant schizophrenia. Journal databases were searched from 1972 to March 2018. The following search terms were used: treatment-resistant schizophrenia, clozapine, barriers, use, prescription rates, implementation, clozaril and prescribing practices. Following a review of the literature, 15 papers were included in the review. Results: The major barriers that were identified included mandatory blood testing, fear of serious side-effects and lack of adherence by the patients, difficulty in identifying suitable patients, service fragmentation, and inadequate training in or exposure to using clozapine. Clinical implications: In view of consistent evidence across the studies on inadequate knowledge and skills as a significant barrier, we suggest that a certification requiring competence in initiating and managing side-effects of clozapine becomes a mandatory requirement in training programmes. Declarations of interest: None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Tiihonen, J., Lönnqvist, J., Wahlbeck, K., Klaukka, T., Niskanen, L., Tanskanen, A., & Haukka, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60742-x · Cited by 1,354
McEvoy, J. P., Lieberman, J. A., Stroup, T. S., Davis, S. M., Meltzer, H. Y., Rosenheck, R. A., Swartz, M. S., Perkins, D. O., Keefe, R. S. E., Davis, C. E., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.4.600 · Cited by 1,018
Lewis, S. W., Barnes, T. R. E., Davies, L., Murray, R. M., Dunn, G., Hayhurst, K. P., Markwick, A., Lloyd, H., & Jones, P. B. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbj067 · Cited by 422
The social and economic burden of treatment-resistant schizophrenia: a systematic literature review
Kennedy, J. L., Altar, C. A., Taylor, D. L., Degtiar, I., & Hornberger, J. C. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e32836508e6 · Cited by 392 · cited 1×
“31 In the UK, NICE has included the extent and the degree of clozapine use in the quality criteria for commis-sioners when commissioning services for mental health.”
Howes, O. D., Vergunst, F., Gee, S., McGuire, P., Kapur, S., & Taylor, D. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.105833 · Cited by 353
Krakowski, M. I., Czobor, P., Citrome, L., Bark, N., & Cooper, T. B. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.6.622 · Cited by 352
Clozapine: a review of clinical practice guidelines and prescribing trends
Warnez, S., & Alessi-Severini, S. (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-102 · Cited by 234 · cited 1×
“8 Studies based on prescription patterns in routine practice almost universally show lower prescriptions of clozapine in individuals with Schizophrenia, even after taking into account potential barriers such as inadequate service provision.”
Psychiatrists’ attitude towards and knowledge of clozapine treatment
Nielsen, J., Dahm, M., Lublin, H., & Taylor, D. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881108100320 · Cited by 213 · cited 6×
“17 However, Nielson et al (2009) found that only 44.9% ( n = 44) would go to clozapine after two anti-psychotics, 13 and about a third 30.6% ( n = 30) 13 of clinicians in one survey and 14% ( n = 19) in another would wait until three adequate trials of antipsychotics prior to initiating clozapine, while 18.4% ( n = 19…”
InfluentialPrior Antipsychotic Prescribing in Patients Currently Receiving Clozapine: A Case Note Review
Taylor, D. M., Young, C., & Paton, C. (2003) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v64n0107 · Cited by 192 · cited 1×
“However, a number of studies 9 – 11 , 16”
Brunette, M. F., Drake, R. E., Xie, H., McHugo, G. J., & Green, A. I. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbl003 · Cited by 142
Practitioner attitudes to clozapine initiation
Gee, S., Vergunst, F., Howes, O., & Taylor, D. (2014) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12193 · Cited by 136 · cited 8×
“…prescribed polypharmacy 21 • Benign ethnic neutropenia 27 Clinician-related barriers • Inadequate knowledge of or experience in clozapine use 17 , 22 – 24 • Fear of side-effects for patient/lack of knowledge about clozapine side-effects 13 , 17 , 19 , 22 , 24 • Lack of adherence to guidance…”
InfluentialGeographic and Clinical Variation in Clozapine Use in the United States
Stroup, T. S., Gerhard, T., Crystal, S., Huang, C., & Olfson, M. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300180 · Cited by 129
Addressing Barriers to Clozapine Underutilization: A National Effort
Kelly, D. L., Freudenreich, O., Sayer, M. A., & Love, R. C. (2017) · Psychiatric Services · doi:10.1176/appi.ps.201700162 · Cited by 123 · cited 5×
“Kelly et al (2015)(18) Psychiatry residents, fellows, and psychiatrists in the state of Maryland Survey with each question rated using Likert scale: 1 = strongly disagree, 5 = strongly agree n = 860 ReR 277 (32%)”
InfluentialTreatment Pathway and Patterns of Clozapine Prescribing for Schizophrenia in New Zealand
Wheeler, A. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k662 · Cited by 93 · cited 2×
“11 In the USA, only six states reported that more than 10% of Medicaid-eligible patients with schizophrenia had received a prescription of clozapine.”
Clozapine: dangerous orphan or neglected friend?
Farooq, S., & Taylor, M. (2011) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.110.088690 · Cited by 73
Self-citationClozapine prescribing in the UK: views and experience of consultant psychiatrists
Tungaraza, T. E., & Farooq, S. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314566808 · Cited by 72 · cited 6×
“…• Fear of side-effects for patient/lack of knowledge about clozapine side-effects 13 , 17 , 19 , 22 , 24 • Lack of adherence to guidance 13 , 17 , 22 • Difficulty identifying suitable patients and unclear diagnoses 22 • Need for intense monitoring 22 , 24 • Perception that patients may not…”
InfluentialSelf-citationBogers, J. P. A. M., Bui, H. N., Herruer, M., & Cohen, D. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.11.022 · Cited by 53
Self-citationAn Initiative to Improve Clozapine Prescribing in New York State
Carruthers, J. W., Radigan, M., Erlich, M. D., Gu, G., Wang, R., Frimpong, E. Y., Essock, S. M., Olfson, M., Castillo, E. G., Miller, G. A., et al. (2016) · Psychiatric Services · doi:10.1176/appi.ps.201500493 · Cited by 43
Gören, J. L., Rose, A. J., Engle, R. L., Smith, E. G., Christopher, M. L. D., Rickles, N. M., Semla, T. P., & McCullough, M. B. (2016) · Psychiatric Services · doi:10.1176/appi.ps.201500506 · Cited by 41
Delay in initiation of clozapine: A retrospective study from a tertiary care hospital in North India
Grover, S., Hazari, N., Chakrabarti, S., & Avasthi, A. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2014.12.046 · Cited by 40 · cited 3×
“…ve patients were • Refusal of blood tests 17 – 19 • Tolerating clozapine and side-effects 17 • Age > 20 19 , 20 • Patients prescribed polypharmacy 21 • Benign ethnic neutropenia 27 Clinician-related barriers • Inadequate knowledge of or experience in clozapine use 17 , 22 – 24 • Fear of…”
InfluentialClozapine: national review of postcode prescribing
Downs, J. M., & Zinkler, M. (2007) · Psychiatric Bulletin · doi:10.1192/pb.bp.106.013144 · Cited by 31
Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns
Apiquián, R., Fresán, A., de la Fuente‐Sandoval, C., Ulloa, R. E., & Nicolini, H. (2004) · BMC Psychiatry · doi:10.1186/1471-244x-4-12 · Cited by 28
Clozapine prescribing in adolescent psychiatry: survey of prescribing practice in in-patient units
Cirulli, G. (2005) · Psychiatric Bulletin · doi:10.1192/pb.29.10.377 · Cited by 27 · cited 1×
“Cirulli (2005)(24) Consultant psychiatrists working in child and adolescent mental health services in-patient unit Survey n = 83 ReR 59 (71%)”
Hematological clozapine monitoring with a point-of-care device: A randomized cross-over trial
Nielsen, J., Thode, D., Stenager, E. N., Andersen, K. Ø., Sondrup, U., Hansen, T. N., Munk, A. M., Lykkegaard, S. E., Gosvig, A., Petrov, I., et al. (2011) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.10.001 · Cited by 27
Antipsychotic prescribing before clozapine in a community psychiatric hospital: a case note review.
Najim, H., Heath, D., & Singh, P. (2013) · PubMed · Cited by 16
Cited by
de Leon, J., Ruan, C.-J., Schoretsanitis, G., & De las Cuevas, C. (2020) · Psychotherapy and Psychosomatics · doi:10.1159/000507638 · Cited by 164
Correll, C. U., Agid, O., Crespo-Facorro, B., de Bartolomeis, A., Fagiolini, A., Seppälä, N., & Howes, O. D. (2022) · CNS Drugs · doi:10.1007/s40263-022-00932-2 · Cited by 162
“This may be due to the side-effect profile of clozapine, the monitoring requirements associated with its use, and a lack of prescribing experience [49, 50].”
BackgroundBach‐Mortensen, A. M., & Verboom, B. (2020) · Research Synthesis Methods · doi:10.1002/jrsm.1447 · Cited by 69
Metadata
- Authors
- Farooq, S., Choudry, A., Cohen, D., Naeem, F., & Ayub, M.
- Venue
- BJPsych Bulletin
- Publisher
- Royal College of Psychiatrists
- Published
- 2018-09-28
- Volume
- 43
- Issue
- 1
- Pages
- 8-16
- ISSN
- 2056-4694 (ISSN-L)
- 2056-4708
- OpenAlex
- W2893591395
- Cited by
- 178
- References
- 29
- FWCI
- 2.32
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.